Summary The utility of the polymerase chain reaction (PCR) as a technique for determining the expression of transforming growth factor ,B (TGF-fl) and of the oestrogen receptor (ER) in clinical breast cancer tissue was examined. PCR analysis was compared with immunocytochemical assays for TGF-,B and for ER. Seventy confirmed breast carcinoma samples were analysed for ER using both techniques with a statistically highly significant concordance (P<0.001) between the two methods. Nineteen samples were observed to be ER positive and 46 samples were found to be ER negative by both techniques. Forty-eight samples were analysed for TGF-,B using both PCR and immunocytochemistry. Of the 24 samples observed to be positive for TGF-,B by immunocytochemistry, all were found to be positive for TGF-,B mRNA (PCR). Similarly, the 24 samples observed to be TGF-,B negative by immunocytochemistry were also negative for TGF-fl mRNA, indicating 100% specificity and 100% sensitivity of the PCR technique. PCR is therefore considered a viable technique for analysis of both ER and TGF-,B in small samples such as fine-needle aspirates.
The oestrogen receptor (ER) content of human breast cancer has been found to be a significant prognostic factor in early breast cancer (Cooke et al., 1979; Knight et al., 1977; Maynard et al., 1978; De Sombre et al., 1979) as well as being a predictor of hormone responsiveness in patients with advanced disease (Paridaens et al., 1980; Dao and Nemoto, 1980; Lippman and Allegra, 1980; Osborne et al., 1980; Rose et al., 1985; Glauber and Kiang, 1992) . The first reliable and reproducible assays to be developed for ER in breast cancer extracts were ligand-binding assays (RLBAs) using radiolabelled specific ligands such as [3H] 17-fl-oestradiol together with various techniques such as dextose-coated charcoal (Korenman and Dukes, 1970; McGuire et al., 1975; Wittliff, 1984) or sucrose gradient sedimentation (Wittliff, 1979) to separate bound and free steroid.
The availability of specific antibodies to ER, as demonstrated by King and Green (1984) , provided the opportunity to determine the presence of receptor proteins by immunoassay methods. The advantages of the ER immunoassay (ERICA) over the ligand-binding assays include greater ease of specimen collection and storage as well as obviating the need for radioactive isotope handling. Immunocytochemistry is rapid and can be performed on much smaller samples, including cytological preparations obtained by fine-needle aspiration. Although such immunological assays have been found to correlate well with RLBAs (King et al., 1985; De Sombre et al., 1986; Jonat et al., 1986; McCarty et al., 1986) , there is a subjective component to the interpretation of results unless advanced image-analysing systems are used. Moreover, the technique does not lend itself to the analysis of multiple prognostic determinants unless a large number of histological or cytological sections are unavailable.
The cellular effects of hormones or drugs that can specifically bind to ER and either induce or block oestrogen-mediated effects has been shown to be indirect, through triggering of growth factor transcription, translation and release. One of the more important of these factors, modulating the growth of cells, is thought to be transforming growth factor # (TGF-f,). The TGF-,Bs constitute a family of transforming growth factors which have been implicated in the control of proliferation of breast cancer cells (Knabbe et al., 1987) . TGF-# has been detected by immunocytochemical techniques in a number of tissues (Hirayama et al., 1992) and also by in situ hybridisation techniques in embryonic tissues (Pelton et al., 1990) . It has been suggested that the growth of human breast tumours may be influenced by autocrine secretion of TGF-fi (Roberts et al., 1988) and altered expression, in cancer cells, of TGF-,Bs in cancers has been reported (Barrett-Lee et al., 1990) . The relationship of TGF-f and ER expression has not, however, been studied extensively in clinical breast cancer.
The aim of this study was to investigate PCR as a tool for the detection of ER and TGF-,B in breast cancer.
Materials and methods
Tissue samples Samples were obtained from breast masses, clinically suspected of being breast cancer, from 115 patients, either by fine-needle aspiration or by needle biopsy. Fine-needle aspirates (FNAs) were obtained by multiple needle passes with a 21 g needle attached to a 10 ml syringe. The needle contents were then expelled into and the needles rinsed five times in 0.5 ml of 50% ethanol in a microfuge tube. An aliquot of each FNA sample was submitted for cytological examination while biopsy samples were submitted for routine paraffin-fixed, haematoxylin-and eosin-stained, histological examination in order to confirm that the material contained tumour cells. The aliquots used for PCR analysis were stored at -700C in the 50% ethanol. Needle biopsies were performed using a Tru-Cut needle (Travenol Labs., Deerfield, IL, USA). A portion of each needle biopsy sample was fixed in 50% ethanol and stored at -70°C. The reaction products of PCR were analysed by electrophoresis on 2% agarose gels (Promega), containing 0.5 mg ml-' ethidium bromide.
ER immunocytochemistry

Southern blotting
The agarose gels were incubated for 45 min in 0.5 M sodium hydroxide, 1.5 M sodium chloride, and twice for 30 min in 1 M Tris-HCl, pH 7.4, 1.5 M sodium chloride. Nucleic acids were transferred for 16 h to nylon membranes (Hybond-N, Amersham, UK), the membranes were washed in 10 x SSC (10 x SSC = 1.5M sodium chloride, 0.15 M sodium citrate), air dried for 30 min and fixed by baking at 80°C for 1 h under vacuum.
Hybridisation with radioactive probes
The plasmid clone, pOR3 (ATCC 57680), with the cDNA insert containing nucleotides 300-1600 of the ER gene (Green et al., 1986) , was obtained from the ATCC. The probe insert was released by digestion with EcoRI restriction enzyme (Boehringer-Mannheim, Germany) and treated by random priming (Random Primed DNA Labelling Kit, Boehringer-Mannheim, Germany) using [32P] dCTP (3000 Ci mmol-') (Amersham, UK). Similarly, the phTGB-2 (ATCC 59954) plasmid clone, containing the cDNA insert including the complete coding sequence of TGF-f,l, was digested with EcoRI to release the probe and labelled using the random primed DNA labelling kit with [32P]-dCTP.
The membranes were prehybridised for 24 h at 420C in 5 x SSC, 50% deionised formamide, 5 x Denhardt's solution (50 x solution = 1% Ficoll, 1% polyvinylpyrrolidone and 1% BSA), 0.5% sodium dodecyl sulphate (SDS), 100 Mg ml-' denatured herring sperm DNA. Hybridisation was performed for 24 h at 42°C in the same buffer but without SDS and with the relevant 32P-labelled probe. The membranes were washed for 5 min in 2 x SSC, 0.5% SDS at room temperature and for 25 min in 2 x SSC, 0.1% SDS, at room temperature. Autoradiography was performed at -700C for 48 h with Hyperfilm-MP (Amersham, UK) with intensifying screens.
Validation of PCR products Specific PCR products were considered to be present if clean products of the predicted size were obtained after amplification. Primers were selected to bridge intron-exon boundaries therefore excluding the presence of contaminating genomic DNA (the product would be larger than predicted if gDNA was present). Positive and negative controls were run simultaneously with negative controls producing no PCR product. Further confirmation was obtained by using Southern blotting and hybridisation with specific radiolabelled probes. Comparison of the results with the two methods was by chi-square analysis.
The study was performed according to the principles of the Declaration of Helsinki and was approved by the Committee for Ethics of Human Research of the University of the Witwatersrand.
Results
Of the 115 samples analysed, 26 were found not to contain any malignant cells by cytological and/or histological evaluation. Of these 25, there were nine cases of fibroadenosis, another six samples in which only fat cells were identified by cytological examination, six that were acellular and another five that contained only blood and/or inflammatory cells. PCR analysis was nevertheless carried out using this material with uniformly negative results for both ER and TGF-f mRNA expression. These samples thus form an important control group over and above the reagent blanks used for each of the PCR procedures.
Of the remaining 89 samples in which tumour cells were detected, there was sufficient material for ER determination by both immunochemistry and by the PCR method in 70. Details of these 70 patients are given in Table II (Table IV) indicating 100% specificity and 100% sensitivity.
Further investigation of the sensitivity of these methods for detection of ER and TGF-fB in samples containing only (57) 42 (60) 28 (40) 9 (13) 38 (54) 10 (14) 13 (19) 14 (20) 56 (80) 0 (0) 42 (60) 28 (40) 59 (84) 7 (10) 4 (6) 11 (16) 27 (38) 4 (6) 28 (40) scanty cell material showed that both ER and TGF-# mRNA could be reliably detected in samples containing as little as 1000 cells per 0.5 ml. No significant differences were found when the frequency of ER expression in Tru-Cut needle biopsy samples (13 specimens, 4/13 ER+ by both techniques) were compared with FNA samples (16/57, 28% ER+ by PCR and 19/57, 33%, ER+ by ERICA).
Discussion
The present study validates PCR as a viable method of detecting expression of ER mRNA from small samples such as FNAs. Out of a total of 70 patients analysed for ER by both PCR and ERICA, 94% of the samples exhibited the same results.
While specificity appears to be good, some attention has to be paid to the question of the sensitivity of the method. Only 70 of the 89 samples could be analysed by both techniques. It should, however, be noted that in all instances in which there was not sufficient material to perform both assays, the difficulty lay in obtaining enough cells for ERICA. All 89 samples containing tumour cells were able to be analysed by PCR with a detection of ER mRNA in 23/89 (26%).
A further consideration regarding the sensitivity of these assays is whether or not they accord with the patient population studied. The frequency of ER expression is known to vary with menstrual status and age (Thorpe et al., 1987) as well as with ethnic origin (Levin et al., 1978; Pegoraro et al., 1986) and is, moreover, an indicator of disease biology (Maynard et al., 1978; Clark et al., 1984) . In this regard, it should be noted that the mean age of the patient included in this study was 52 years, 43% were premenopausal, 60% were black and 40% presented with stage 4 disease. For the population studied, the expected frequency of ER expression would appear to be in the range observed in the current investigation.
While the two techniques were concordant in most instances, there were a few discrepant results using the two methods. Four (6%) samples showed positive ER protein expression (ERICA) but no mRNA expression (PCR). One possible explanation for this finding would be a mutation within the chosen primer regions resulting in a failure to detect the appropriate PCR product. The segment of ER mRNA chosen for amplification by PCR in this study was located predominantly in the DNA-binding domain, while the specificity of the monoclonal antibody used for the (Knabbe et al., 1987) . Whether this model is applicable to in vivo human breast cancer, remains to be established and a reliable, sensitive method for detecting the transcription of the gene for this growth factor would appear to be extremely useful for such studies.
While PCR can perpetuate and exponentially amplify even minute errors in the templates it appears to be a viable technique for analysis of both ER and TGF-,B. Only a small sample of material is required for analysis (as few as 1000 cells), it is a rapid technique and subjective interpretation errors and interobserver variations, which occur in immunocytochemical techniques, can be avoided.
